Table 2.
Paired-data analysis for BR-CT versus placebo
| Variable | Placebo (n = 44) (SD) |
BR-CT (n = 44) (SD) |
Δ (SD) [95% CI] |
dunb δ [95% CI] |
p value | Correlation |
|---|---|---|---|---|---|---|
| RAVLT_D | 42.68 (7.68) | 47.95 (8.67) |
5.27 (6.52) [3.28, 7.25] |
0.632 [0.36, 0.91] |
< 0.001 | 0.69 |
| RAVLT_I | 8.36 (2.85) | 10.09 (2.59) |
1.72 (3.28) [0.72, 2.72] |
0.622 [0.25, 1.01] |
0.001 | 0.27 |
| Digit span F | 5.56 (1.12) | 5.59 (0.97) |
0.02 (1.19) [– 0.33, 0.38] |
0.021 [– 0.31, 0.35] |
0.900 | 0.37 |
| Digit span B | 3.65 (1.01) | 3.72 (0.92) |
0.06 (1.10) [– 0.26, 0.40] |
0.069 [– 0.26, 0.40] |
0.685 | 0.35 |
| SDMT | 69.0 (12.01) | 64.56 (15.02) |
–4.43 (15.79) [– 9.23, 0.37] |
0.320 [– 0.67, 0.02] |
0.070 | 0.33 |
| FAB | 15.90 (1.42) | 16.31 (1.11) |
0.40 (1.2) [0.02, 0.79] |
0.314 [0.01, 0.61] |
0.037 | 0.53 |
| COWAT/FAS | 32.52 (9.67) | 36.15 (8.00) |
3.63 (6.79) [1.57, 5.70] |
0.403 [0.16, 0.65] |
0.001 | 0.72 |
| BDI | 5.79 (5.39) | 7.34 (6.19) |
1.54 (3.63) [0.44, 2.64] |
0.261 [0.07, 0.45] |
0.007 | 0.81 |
| STAI Y1 | 33.95 (7.82) | 35.43 (10.52) |
1.47 (6.71) [– 0.56, 3.51] |
0.157 [– 0.05, 0.37] |
0.152 | 0.77 |
| STAI Y2 | 38.59 (9.53) | 39.34 (10.32) |
0.75 (5.15) [– 0.81, 2.31] |
0.074 [– 0.07, 0.22] |
0.340 | 0.87 |
| PMRQ P | 19.31 (5.27) | 19.68 (5.93) |
0.36 (3.48) [– 0.69, 1.42] |
0.064 [– 0.12, 0.24] |
0.493 | 0.81 |
| PMRQ R | 18.43 (4.52) | 19.09 (4.92) |
0.65 (3.01) [– 0.25, 1.57] |
0.137 [– 0.05, 0.32] |
0.154 | 0.80 |
| PMRQ TOT | 37.75 (9.31) | 39.0 (10.15) |
1.25 (6.11) [– 0.60, 3.11] |
0.126 [– 0.06, 0.31] |
0.183 | 0.81 |
Data is presented as mean () and standard deviation (SD). The difference will attain significance at the p < 0.05 level if the 95% CI excludes zero
CI confidence interval, dunb (δ) unbiased Cohen’s d